AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -146.41M | -171.68M | -165.67M | -167.87M | -162.86M |
| Total Depreciation and Amortization | 28.82M | 2.80M | 33.86M | 64.84M | 65.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.99M | 73.90M | 48.13M | 13.03M | 15.15M |
| Change in Net Operating Assets | -70.69M | -9.57M | 2.83M | 11.60M | -25.84M |
| Cash from Operations | -131.30M | -104.55M | -80.84M | -78.40M | -108.56M |
| Capital Expenditure | -42.77M | -48.56M | -58.15M | -64.89M | -78.40M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 130.52M | 96.87M | 73.67M | 164.33M | 199.81M |
| Cash from Investing | 87.75M | 48.32M | 15.53M | 99.43M | 121.41M |
| Total Debt Issued | 29.73M | 23.53M | 19.30M | 16.63M | 13.50M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.65M | -9.42M | -9.42M | -722.00K | -729.00K |
| Cash from Financing | 14.08M | 14.11M | 9.88M | 15.91M | 12.77M |
| Foreign Exchange rate Adjustments | 1.10M | -1.35M | -442.00K | -1.25M | -2.62M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.37M | -43.48M | -55.88M | 35.69M | 23.01M |